Results 111 to 120 of about 4,640 (210)

Structure-Based Virtual Screening and Mechanistic Characterization of Methotrexate and Selinexor as Potent Anti-Melanogenic Agents via Multi-Pathway Suppression of MITF. [PDF]

Cells
Zhang Z, Li H, Shi Z, Bai X, Yin P, Yang L.   +5 more
europepmc   +1 more source

Sequential therapy with decitabine and an XPO-1 inhibitor followed by allogeneic hematopoietic stem cell transplantation in MDS with biallelic TP53 inactivation patients : a preliminary case series. [PDF]

Exp Hematol Oncol
Ren Y, Lang W, Xu Y, Mei C, Huang X, Wang S, Qian J, Tong H.   +7 more
europepmc   +1 more source

Targeting the nuclear export receptor exportin-1 in acute myeloid leukaemia: From biology to clinical translation. [PDF]

Clin Transl Med
Liu Y, Yun X, Ding W, Li S, Liu H.
europepmc   +1 more source

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial. [PDF]

J Clin Oncol
Bose P, Ali H, Al-Ali HK, Garcia-Gutierrez V, Grosicki S, Grudeva-Popova Z, Harrison C, Hong J, Hou HA, Kwiatek M, Loschi M, Passamonti F, Patriarca A, Podoltsev N, Rampal R, Tantravahi S, Urian LG, Chai Y, Taverna P, Mark T, Sadiq A, Rangwala R, Vachhani P, Mascarenhas J, SENTRY Trial Investigators.   +24 more
europepmc   +1 more source

Exportin 1 Inhibitor Combined With Venetoclax Induces Apoptosis in Myelodysplastic Syndrome by Mitochondria-Induced Apoptosis Pathway. [PDF]

J Clin Lab Anal
Liu X, Huang L, Wang J, Guo Y, Shen H, Zhao X, Yue L, Liu Z, Fu R.   +8 more
europepmc   +1 more source

Selinexor (Xpovio™)

Oncology Times, 2020
openaire   +2 more sources

Selinexor plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: a multicenter, open-label, phase 1 study. [PDF]

Blood Adv
Ali H, Mohan S, Kishtagari A, Prchal JT, Maher K, Chai Y, Gudi G, Taverna P, Mark T, Tantravahi SK.   +9 more
europepmc   +1 more source

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial. [PDF]

Br J Haematol
Delimpasi S, Špička I, Butler JP, Stevens DA, Mesa MG, Bygrave C, Merlo GM, la Porte C, Dimopoulos MA.   +8 more
europepmc   +1 more source

FASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target. [PDF]

J Transl Med
Doldi V, Ciniselli CM, Aurelio C, Favini E, Veronese SM, Bozzi F, Kusamura S, Baratti D, Martini S, Verderio P, Deraco M, Folini M, Gandellini P, Pasquali S, Zaffaroni N.   +14 more
europepmc   +1 more source

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape. [PDF]

ESMO Open
Gay F, Buda G, Petrucci MT, Bolli N, Cea M, Derudas D, Mangiacavalli S, Montefusco V, Antonioli E, Barilà G, Basso M, Bertazzoni P, Bertuglia G, Bianco R, Carlisi M, Giudice MLD, Della Pepa R, Fazio F, Franceschini L, Furlan A, Gozzetti A, Liberatore C, Mancuso K, Martino EA, Mele G, Monaco F, Morè S, Paris L, Pavan L, Pezzatti S, Rago A, Ribolla R, Roncato R, Rossini B, Sgherza N, Vassallo F, Vincelli DI, Za T, Musto P, Zamagni E.   +39 more
europepmc   +1 more source